A training program on:
Need budget approval? Think your team could benefit from this program? Download a summary page of this MAP Program to easily share!
On your time and applied to your business environment
Immediately access e-modules thoroughly covering the shifting healthcare landscape
E-modules accessible for 90 days and many live discussion dates to select from
Live discussion presents an opportunity to discuss learning relevant to you
Understanding your customer's business allows for more meaningful conversations
Insightful information via 3 e-learning modules
E-learning modules viewable on mobile or desktop
Access to modules available for 90 days after purchase
Real-world application via Live Discussion
Engage with peers and a healthcare marketplace SME
Multiple Live Discussion dates to choose from
A frequently updated list of scheduled live webinar discussions (in Eastern Time). Enroll in the session time that works for you after purchasing the program.
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
|
29
|
30
|
1
|
2
|
3
|
4
|
5
|
As the market access environment changes, relevant topics will be covered through new programs. Subscribe below to be the first to know about new MAP Program topics and added dates for existing Programs.
Understanding product access doesn’t stop here. Learn how other market trends could be impacting your customers and thus your business strategies!
Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On top of that, providers face the difficulty of helping patients
The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps
The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact.
